

中文標題：HLA 半相合移植治療復發與頑固型何杰金氏淋巴癌單一中心經驗報告

英文標題：Haploidentical Hematopoietic Stem Cell Transplantation for the Treatment of Relapsed and Refractory Hodgkin's Lymphoma

作者：梁世昕¹，林精湛²，葉士芄²，白禮源²

服務單位：¹ 佛教慈濟醫療財團法人大林慈濟醫院內科部 ² 中國醫藥大學附設醫院血液腫瘤科

Introduction/Background

The prognosis of relapsed and refractory Hodgkin's lymphoma (HL), is poor, especially those who had relapsed disease after autologous hematopoietic stem cell transplantation (HSCT). Recently, haploidentical HSCT shows promising outcome for this group of patients.

Methods

Here we report 6 cases of relapsed and refractory Hodgkin's lymphoma treated with haploidentical HSCT at China Medical University Hospital. 5 of these had prior autologous HSCT. Another 1 had refractory disease to salvage chemotherapy as well as Nivolumab. 5 patients received salvage Brentuximab Vedotin and achieved complete remission (1 patient) or good partial remission (4 patients) before haploidentical HSCT. All the 6 patients received TBI 200cGy and Fludarabine/Cyclophosphamide as conditioning and post-transplant Cyclophosphamide (PTCy) plus low dose ATG/CSA/short course MMF as GVHD prophylaxis.

All the 5 patients had complete donor chimerism and PET negative complete remission after haploidentical HSCT. None had acute GVHD. 1 patients had limited stage chronic GVHD. With follow-up 8 months to 40 months, all the patients remained in PET negative complete remission.

Conclusion

Haploidentical HSCT using PTCy strategy with RIC conditioning is an effective and safe treatment for relapsed and refractory Hodgkin's lymphoma.